Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.1.1.67 (
thiopurine methyltransferase
)
551
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Azathioprine metabolism is influenced by activity of the enzyme
thiopurine S-methyltransferase
(
TPMT
), which varies markedly between individuals. In this study we examined the influence of
TPMT
gene polymorphisms on azathioprine dose 1 year after renal transplantation.
TPMT
coding and promoter genotypes were determined using PCR-based assays. Azathioprine dose,
white cell
count, and intercurrent events throughout the first year after renal transplantation were ascertained from contemporaneous clinical notes. All patients analysed ( n=172) received an initial azathioprine dose of 1.5 mg/kg per day. Twelve individuals with one variant
TPMT
coding allele were detected (*3A n=11, *3C n=1). Of these, 58% required azathioprine dose reduction because of leucopenia, compared to only 30% of homozygous wild-type patients ( P=0.04). A significant correlation between the presence of >/=11 variable number tandem repeats (VNTRs) in the
TPMT
promoter and reduction in azathioprine dose was also identified ( P=0.001). We concluded that when azathioprine is administered at an initial dose of 1.5 mg/kg per day, both coding and promoter
TPMT
polymorphisms influence the dose tolerated.
...
PMID:The impact of thiopurine S-methyltransferase polymorphisms on azathioprine dose 1 year after renal transplantation. 1534 17